ClinicalTrials.gg
Status unknownNCT03435666CapecitabineUpdated Feb 19, 2018

A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition

A Phase 1 interventional study of Capecitabine and XELODA in Colon Cancer and Breast Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing capecitabine in Colonic Neoplasms — 3 open to participants now, 7 under way, 3 of them phase 3. Capecitabine · Colonic Neoplasms.

Planned enrollment
27th of 48
45 · median 51
Started
2018
the only one that year
Phase 1
9 of 53
none open now
Registered
43rd of 53
by date

Among the 53 studies testing capecitabine in Colonic Neoplasms, this one is the 27th largest by planned enrollment of the 48 interventional ones that give a count, is the only one that started in 2018, is one of 9 in phase 1, and was the 43rd registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

3 of the 53 studies testing capecitabine in Colonic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 71 (22%) stop at 75 or younger; 19 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing capecitabine in Colonic Neoplasms, or all of them as a file.
02

Study summary

Purpose: To demonstrate the bioequivalence between Capecitabine Tablets 500 mg of Qilu Pharmaceutical Co., Ltd, China in comparison with XELODA® (Capecitabine) Tablets 500 mg, Distributed by Genentech USA, Inc.

Design: two treatment, three period, three sequence, reference replicate crossover, single dose.

Test Drug: Capecitabine Tablets; Reference drug: XELODA Sample size: Around 45 patients will be enrolled to have at least 39 evaluable patients in the study.

Read the detailed description

Objectives:

Primary Objective: To demonstrate the bioequivalence between Capecitabine Tablets 500 mg of Qilu Pharmaceutical Co., Ltd, China in comparison with XELODA® (Capecitabine) Tablets 500 mg, Distributed by Genentech USA, Inc. following a single oral dose administration in adult cancer patients under fed condition.

Secondary Objective: To monitor the safety and tolerability profile of the subjects exposed to the Investigational Medicinal Product.

Study Design: a randomized, multicenter, open label, balanced, two treatment, three period, three sequence, reference replicate crossover, single dose, bioequivalence study under fed conditions.

Number of subjects: at least 39 evaluable patients Mode of Administration for Test and Reference product: Patient will be randomized to one of the three treatment sequences i.e. TRR, RTR or RRT. Where T-Test drug and R-Reference drug. The study medication will be administered in the morning of Day 1 (Period I of the study), Day 2(Period II of the study) and Day 3 (Period III of the study).

Since, the patients are on a twice daily dosing regimen the patients should receive their usual dose of capecitabine as per their dosing regimen between each subsequent study periods. The drug product used to administer the dose between the study periods can be the same or any approved product as that used by the patients for their current dosing regimen. The morning and evening doses will be based on BSA.

Blood collection times: pre-dose blood sample of 03 mL (00.00) will be collected within 5 minutes before dosing in each period of the study. After dosing in each period (Day 1, Day 2 and Day 3), the post-dose blood samples of 03mL each will be drawn at 0.17 (10min), 0.33 (20min), 0.50 (30 min),0.67 (40min), 0.83 (50min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours following drug administration.

Bioequivalence Criteria:

For Capecitabine, the bioequivalence will be concluded based on within-subject standard deviation of reference formulation, termed as SWR.

Reference - Scale Average Bioequivalence Approach:

When SWR ≥ 0.294 for any of the primary pharmacokinetic parameters, below mentioned both the criteria must be satisfied: The 95% upper confidence bound for (μT- μR)2/S2WR determined must be ≤ θ, or equivalently, a 95% upper confidence bound for (μT- μR)2-θ*S2WR must be ≤ 0; and the point estimate (test/reference geometric mean ratio) must fall within [0.80, 1.25].

Conventional Average Bioequivalence Approach:

When SWR \< 0.294 for any of the primary pharmacokinetic parameters, 90% confidence interval for the geometric least square means ratio (T/R) of that parameter must be fall within the acceptance range of 80.00% to 125.00%.

03

Conditions studied

  • Colon Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female patient of age between 18 to 60 years (both inclusive).
  2. Patients with have histopathologically / confirmed Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred.

    Or Patients with histopathologically /cytologically confirmed colorectal carcinoma with evidence of when treatment with fluoropyrimidine therapy alone is preferred Or Patients with histopathologically /cytologically confirmed breast cancer with evidence of metastasis

  3. Resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.
  4. Cancer patients already receiving a stable twice-daily dosing regimen of capecitabine (who have completed at least one cycle of chemotherapy) as prescribed by the reference product label (i.e. 1250 mg/m2, twice daily, equivalent to 2500 mg/m2 total daily dose, for two-weeks followed by a one-week rest period given as three-week cycles)
  5. (ECOG) performance status of 0-2.
  6. Adequate cardiac function [ (LVEF) ≥ 50 %]
  7. Patient with adequate bone marrow( ≥ 1500/mm3, count ≥ 100,000/mm3 , ≥ 9.0 g/ dL); renal (Serum Creatinine ≤ 1.5 times and ≥ 51 to 80 mL/min [Cockroft and Gault]) and hepatic function ( ≤ 1.5 times ULN, /AST ≤ 3 times ULN (≤ 5 x ULN if liver metastases present)) .
  8. Patient willing and able to give written for participation in the study and comply with the study protocol.
  9. No persistent toxicities from prior medications at screening.
  10. Subject with clinically acceptable chest X-Ray (P/A view) whose X-Ray was taken not more than 3 months prior to screening.
  11. Females of (FOCP) must agree to use an acceptable method of such as sexual abstinence or at least 2 reliable modes of contraception, one of which must be a double-barrier method (e.g., condom with spermicidal gel or diaphragm with spermicidal gel) or IUD or vaginal spermicidal suppository from screening until 6 months after last dose of study drug. [Note: Use of hormonal contraception (pills/hormonal intrauterine device etc,) is not allowed].

    OR females defined as at least 12 consecutive months with no menses without an alternative medical cause OR Surgically sterilized females with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy. Females without documented evidence of surgery and those who have undergone tubal ligation will be considered of child bearing potential.

  12. Male patient must agree to use an acceptable method of birth control such as sexual abstinence or barrier method of contraception (i.e. condom) from screening until 3 months after last dose of study drug. Subject agrees to accept the risk that pregnancy in female partner could still result despite using birth control devices.
  13. Cancer patients should preferably be on monotherapy. However, cancer patients receiving concomitant drug(s) are allowed to participate, provided:

    • The concomitant medication is the same for all the study period and clearly documented.
    • Patients do not require any change their concurrent medications during the study period
    • The concurrent medications do not interfere with the assay for measuring the drug in plasma.

Exclusion criteria

Exclusion Criteria:

  1. Known or to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil, or
  2. Patients with known DPD (Dihydropyrimidine Dehydrogenase) deficiency.
  3. Prior unanticipated severe reaction to Capecitabine or metabolites and to fluoropyrimidine therapy
  4. Patients with a prior history of coronary artery disease,
  5. Patients receiving phenytoin, warferin, other coumarin-derivative anticoagulants, leucoverin, CYP2C9 at the time of screening or anticipated use of these drugs during the study period. [If the subject was on any of these drugs before screening, a wash out period of at least 5 half-lives must have elapsed since the last dose of such drug.]
  6. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) . Patients with previously treated (> 6 months of screening) and are now stable and asymptomatic are allowed.
  7. Presence of active infections
  8. Any of the following cardiac conditions:

    1. Unstable angina
    2. Myocardial infarction within the past 6 months
    3. (New York State Heart Association) class II-IV heart failure
    4. Severe uncontrolled ventricular arrhythmias
    5. pericardial disease
    6. Electrocardiographic evidence of acute ischemic or active conduction system abnormalities
    7. Any other cardiac illness that could lead to a safety risk to the patient in case of enrolment in the study
  9. Patient having abnormal serum calcium level at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
  10. Patients who have had experienced a severe mucocutaneous reaction during prior capecitabine treatment.
  11. Pre-existing motor or sensory neurotoxicity of a severity ≥ grade 2 by criteria.
  12. Known, existing uncontrolled coagulopathy.
  13. Subject with positive (HIV) infection, a positive hepatitis screen including surface antigen, and HAV antibodies.
  14. Subject with clinically significant active infection and symptoms of noninfectious pneumonitis as judged by investigator.
  15. Use of any recreational drugs or history of drug addiction.
  16. Have a history of alcohol or drug-dependence as per criteria during the 6-month period immediately prior to Screening
  17. Positive test results for urine drug scan (except for prescribed benzodiazepines) or breath alcohol test at baseline
  18. Subject with a history of difficulty in donating blood or difficulty in accessibility of veins.
  19. An unusual or abnormal diet, for two weeks prior to receiving any medication and throughout subject's participation in the study, for whatever reason e.g. because of fasting due to religious reasons.
  20. Receipt of any Medicinal Product within the past 30 days of randomization or has less than 5 half life from previous IMP receipt.
  21. History of donation of blood/loss of blood (without replenishment) (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product in the study.
  22. History of administration of within the past 4 weeks of screening or scheduled to receive a live vaccine during the study period until end study assessments.
  23. Subject with any factor/condition preventing oral consumption of tablet.
  24. Subject with post-major surgery (major surgery is defined as a procedure requiring general anesthesia), open , or significant traumatic injury or with unhealed wound or not recovered from prior major surgery within 4 weeks from screening.
  25. Any severe, acute, or chronic medical, psychiatric or social condition; or laboratory abnormality that may increase the risk of trial participation or investigational agent administration, may interfere with the process and/or with compliance with the requirements of the trial, or may interfere with the interpretation of the trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Capecitabine

    Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.

    Drug: Capecitabine · Drug: XELODA

  • Active comparator
    XELODA

    XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.

    Drug: Capecitabine · Drug: XELODA

Interventions

  • Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.

  • DrugXELODA

    Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma Capecitabine concentration.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

  2. AUC0-t

    The area under the plasma concentration time curve from zero to the last measurable concentration.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

Secondary outcomes

  1. AUC0-∞

    The area under the plasma concentration time curve from zero to infinity.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

  2. Tmax

    Time of the maximum measured plasma concentration.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

  3. Kel

    The elimination rate constant associated with the terminal (log-linear) portion of the curve. Estimated by linear regression of time vs. log concentration.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

  4. t½

    The terminal elimination half-life calculated by 0.693/Kel.

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

  5. AUC_%Extrap_obs

    Percentage of AUC0-∞ to extrapolation from Tlast to infinity

    Time frame: Pre-dose, 0.17 (10 min), 0.33 (20 min), 0.50 (30 min), 0.67 (40 min), 0.83 (50 min), 1.00, 1.25 (1h15min), 1.50 (1h30min), 1.75 (1h45min), 2, 2.25 (2h15min), 2.5 (2h30min), 2.75 (2h45min), 3.00, 3.50 (3h30min), 4.00, 5.00, 6.00, 7.00, and 8.00 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2018; primary completion for Oct 2018, 5 months later.

Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's planned 5 months is below that.

Counting every sponsor, half of 116 studies reached it within 48 months; a quarter within 32 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2018
First posted
Feb 19, 2018
StartEst.
May 2018
Primary completionEst.
Oct 2018
CompletionEst.
Nov 2018
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03435666
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
May 2018 (estimated)
Primary completion
Oct 2018 (estimated)
Completion
Nov 2018 (estimated)
Last update
Feb 19, 2018

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion